Yupelri Solution
Product Images NDC 49502-806

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Yupelri (NDC 49502-806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Revefenacin Structural Formula (Image 01)

Chemical structure of revefenacin, the active ingredient in YUPELRI inhalation solution (175 ug/3mL) by Viatris Specialty LLC.*

FDA Label Image

Figure 1: Ls Mean Change From Baseline In Trough Fev1 (ml) Over 12 Weeks (trial 1) (Image 02)

A line graph showing the least squares mean change from baseline in FEV1 (mL) over study days (Baseline to Day 85) comparing YUPELRI 175 mcg versus Placebo. The YUPELRI group shows an increase in FEV1, while the Placebo group shows little to no improvement.*

FDA Label Image

Figure 2: Ls Mean Change From Baseline In Trough Fev1 (ml) Over 24 Hours Day 84 (trial 1 Subset) (Image 03)

A line graph showing the least squares mean change from baseline in FEV1 (mL) over time after dosing. Two treatments are compared: YUPELRI 175 mcg represented by circles and placebo represented by triangles. The x-axis shows post-dose time points from 5 minutes to 24 hours. YUPELRI treatment shows a positive change in FEV1 over time, while placebo shows a negative or minimal change.*

FDA Label Image

Instructions For Use Figure 1 (Image 04)

An instructional illustration showing hands removing a vial from its protective pouch, labeled as Figure 1. The vial is clearly indicated, demonstrating the step to take the vial out of the packaging.*

FDA Label Image

Instructions For Use Figure 2 (Image 05)

An instructional illustration showing two hands twisting open the top of a vial. The image is labeled as Figure 2 and includes a direction to 'Twist open the top of vial.' This likely demonstrates the initial step for using the product YUPELRI inhalation solution.*

FDA Label Image

Instructions For Use Figure 3 (Image 06)

An instructional diagram showing a hand holding a medication vial above a nebulizer device. The vial is positioned to dispense solution into the nebulizer cup (reservoir). Key parts are labeled: 'Vial,' 'Nebulizer,' and 'Nebulizer cup (reservoir).' This illustrates the process of adding medication solution to the nebulizer for inhalation.*

FDA Label Image

Instructions For Use Figure 4 (Image 07)

Illustration showing components of a respiratory inhalation device for YUPELRI (revefenacin) solution. The diagram labels the mouthpiece and expiratory valve, indicating the assembly sequence with an arrow directing the mouthpiece toward the valve.*

FDA Label Image

Instructions For Use Figure 5 (Image 08)

An instructional diagram illustrating the components of a respiratory inhalation device setup for YUPELRI (revefenacin) solution. It labels the compressor, tubing, nebulizer, and mouthpiece, showing how these parts connect for delivering the medication via nebulization.*

FDA Label Image

Instructions For Use Figure 6 (Image 09)

An instructional illustration showing a person using a respiratory inhalation device that contains a solution medication. The person is holding the device to their mouth and inhaling. A clock icon with the text '8 minutes' is displayed, indicating a time-related instruction for use.*

FDA Label Image

Image 11

Flat layout of the YUPELRI (revefenacin) inhalation solution packaging label for 175 mcg/3 mL strength. The label highlights the product as a respiratory inhalation solution for oral use, with a package size of 30 sterile unit-dose vials. The labeler is Viatris Specialty LLC. The design features green and white colors with logos for Theravance Biopharma and Mylan.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.